Welcome to our dedicated page for PepGen SEC filings (Ticker: PEPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PepGen Inc. filings document the regulatory record of a clinical-stage biotechnology company developing Enhanced Delivery Oligonucleotide therapies for neuromuscular and neurological diseases. Its Form 8-K disclosures cover financial results, corporate presentations, clinical data updates for PGN-EDODM1, FDA-related regulatory matters involving FREEDOM2-DM1, and other business updates tied to its development pipeline.
The company’s proxy materials describe annual meeting matters, director elections, auditor ratification, board structure, executive compensation and stockholder voting mechanics. Other filings address officer appointments, inducement grants, stock-option plans, option repricing, common-stock compensation arrangements and related governance approvals. Together, the filings outline PepGen’s clinical-development disclosures, capital and equity incentive structure, risk-facing regulatory events and public-company governance practices.
PepGen Inc. reported second-quarter 2026 results and updates on its myotonic dystrophy type 1 program. Cash, cash equivalents and marketable securities were $117.2 million as of June 30, 2026, which the company expects will fund operations into the fourth quarter of 2027. For the quarter, research and development expenses were $12.5 million and general and administrative expenses were $6.4 million. Net loss was $17.8 million, or $(0.26) per share, compared with a $23.1 million loss, or $(0.70) per share, a year earlier.
An independent Data and Safety Monitoring Board recommended advancing the Phase 2 FREEDOM2-DM1 multiple ascending dose trial of PGN-EDODM1 into the highest dose cohort of 12.5 mg/kg with no protocol changes, and dose escalation in the open-label extension from 5 mg/kg to 10 mg/kg. The 10 mg/kg cohort is fully enrolled, with 7 of 8 participants having completed dosing; data are expected in November. Results from the 12.5 mg/kg cohort are expected in the first half of 2027, and an update from the open-label extension is expected by early January.
PGN-EDODM1, which uses PepGen’s Enhanced Delivery Oligonucleotide platform to target the RNA mechanism underlying DM1, has U.S. Orphan Drug and Fast Track designations and Orphan Designation in the EU. It remains an investigational therapy, with no regulatory approvals to date.
PepGen Inc. is a clinical-stage biotech focused on its lead oligonucleotide candidate PGN‑EDODM1 for DM1, after discontinuing its DMD program PGN‑EDO51 in May 2025. For the quarter ended June 30, 2026, it reported a net loss of $17.8 million, improved from $23.1 million a year earlier, as research and development spending declined to $12.5 million and general and administrative expenses were $6.4 million.
For the first six months of 2026, PepGen’s net loss was $35.6 million versus $53.3 million in 2025, driven mainly by lower manufacturing and clinical costs following the DMD wind‑down. The company held $117.2 million in cash, cash equivalents and marketable securities as of June 30, 2026, and believes this will fund currently planned operations into the fourth quarter of 2027. PGN‑EDODM1 has shown dose‑dependent splicing correction up to 53.7% in a Phase 1 study, and a Phase 2 FREEDOM2 trial is progressing with 10 mg/kg data expected in November 2026 and 12.5 mg/kg data in the first half of 2027. PepGen remains highly dependent on the success of PGN‑EDODM1 and anticipates needing substantial additional capital over time as it advances development.
PepGen Inc. reported a compensation-related transaction involving an option grant linked to RA Capital-managed entities. An option over 34,000 shares of common stock was awarded at an exercise price of $1.79 per share, expiring on June 17, 2036.
The option will vest in full on the earlier of the first anniversary of the grant date or PepGen’s next annual stockholder meeting, subject to continued board service by Dr. Resnick. Under his arrangement with RA Capital, any net cash or stock from exercising the option will benefit RA Capital Healthcare Fund, RA Capital Nexus Fund II and a separately managed account, offsetting advisory fees, and the reporting persons disclaim beneficial ownership except for any pecuniary interest.
PepGen Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026, where shareholders voted on director elections and auditor ratification. A quorum was reached, with 54,650,845 shares present or represented by proxy out of 69,169,215 shares entitled to vote.
Stockholders elected three Class I directors—Howard Mayer, M.D., Joshua Resnick, M.D., M.B.A., and Lisa Wyman, M.S.—to serve until the 2029 annual meeting. Each nominee received tens of millions of votes in favor, with additional broker non-votes recorded.
Stockholders also ratified the appointment of KPMG LLP as PepGen’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 54,556,255 votes for, 77,083 against, and 17,507 abstentions.
PepGen Inc. reported that director Lisa Wyman received a grant of stock options covering 34,000 shares of common stock. The options have an exercise price of $1.79 per share and expire on June 17, 2036. They vest in full on the earlier of the first anniversary of the grant date or the next annual meeting, subject to continued service as a director.
PepGen Inc. reported that director Joshua Resnick received a grant of stock options covering 34,000 shares of Common Stock at an exercise price of $1.79 per share, expiring on June 17, 2036.
The option vests in full on the earlier of the first anniversary of the grant date or the next Annual Meeting, with vesting stopping if he ceases to serve as a director unless the Board decides otherwise. Under his arrangement with RA Capital Management, L.P., Resnick holds this option for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund II, and a separately managed account, must turn over any net cash or stock on exercise to RA Capital, and disclaims beneficial ownership of the option and underlying shares.
PepGen Inc. director Howard Mayer received a grant of stock options covering 34,000 shares of common stock. The options have an exercise price of $1.79 per share and expire on June 17, 2036. This grant is compensation-related and does not represent an open-market purchase or sale of shares.
According to the vesting terms, the option vests in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting, with vesting stopping if he ceases to serve as a director unless the board decides otherwise. Following this grant, Mayer holds 34,000 options directly.
PepGen Inc. director Mitchell H. Finer received a grant of stock options covering 34,000 shares of common stock. The options carry an exercise price of $1.79 per share and expire on June 17, 2036.
The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting, and vesting stops if he ceases to serve as a director unless the board decides otherwise. Following this grant, he holds 34,000 stock options directly, as reported in this filing.
PepGen Inc. director Habib J. Dable received a grant of stock options covering 34,000 shares of common stock. The options have an exercise price of $1.79 per share and expire on June 17, 2036.
The award vests in full on the earlier of the first anniversary of the grant date or the next Annual Meeting, subject to continued board service unless the board decides otherwise. Following this grant, Dable holds 34,000 options directly, and the filing shows no open-market buying or selling.
PepGen Inc. director Heidi Henson received a grant of stock options covering 34,000 shares of common stock. The options have an exercise price of $1.79 per share and expire on June 17, 2036.
These options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting, subject to continued service on the board unless the board determines otherwise.